Impact Factor
3.32
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
3.29
695 total citations
h5-index
45
h5 depth signal
Cited share
32.7%
73 of 223
Total citations
695
Citation footprint
Metric signal
4.43
External metric anchor
Self-citation
1.3%
9 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
507
Germany
67
Canada
61
United Kingdom
53
Italy
52
Citing Fields of Research
Lymphomas
381
Hematology
279
Immunology
181
Oncology
74
Cancer, Autophagy & Apoptosis
69
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
721
Articles tracked across the journal lifetime
Indexed publication set
223
73 cited publications
Last 12 months
155
12.9 publications/month
Open access share
10.3%
16 OA publications in the last year
Leading citing country
United States
507 citing publications
Leading citing field
Lymphomas
381 citing publications
Latest tracked publication
12 October 2026
10 recent records available
Coverage & Indexing History
v1n1, July 2020-
v1n1, July 2020-
Active Coverage
Research Focus & Classification
Indexed Subjects
Lymphomas
Hematology
Immunology
Issuing & Sponsoring Bodies
issuing body
American Association for Cancer Research
Broad Categories
Hematology
Neoplasms
Lymphomas
MeSH Descriptors
Hematologic Neoplasms.
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1158/2643-3230.bcd-26-0260
Open DOI
CD19 CAR T-cell Escape in Large B-cell Lymphoma: Antigen Density Matters after All
Summary: In this issue of Blood Cancer Discovery, Corona, Gillmor, and colleagues show that quantitative CD19 density measured before chimeric antigen receptor (CAR) T-cell infusion stratifies progression-free survival in large B-cell ly...
02
DOI 10.1158/2643-3230.bcd-26-0080
Open DOI
Spatial Profiling Identifies a Distinct and Topographically defined Tumor Microenvironment that Emerges during Multiple Myeloma Evolution
The pathobiology of multiple myeloma is influenced by cells of the bone marrow (BM), but whether tumor support is organized in a spatially defined tumor microenvironment (TME) remains unclear. Using spatial transcriptomics and imaging ma...
03
DOI 10.1158/2643-3230.bcd-26-0028
Open DOI
Phosphorylation Protects Oncogenic RAS from LZTR1-Mediated Degradation
Oncogenic KRAS and NRAS mutations are common in hematologic malignancies, but their signaling in this context remains less well characterized than in carcinomas. Using multiomics screens in multiple myeloma, we sought to identify regulat...
04
DOI 10.1158/2643-3230.bcd-26-0116
Open DOI
In Vivo CAR T-cell Therapy: Determinants of Response and Durability
In vivo chimeric antigen receptor (CAR) T-cell therapy generates engineered lymphocytes inside the patient, bypassing leukapheresis, ex vivo manufacturing, and, in many programs, lymphodepletion. Studies in relapsed or refractory multipl...
05
DOI 10.1158/2643-3230.bcd-26-0159
Open DOI
Personalized Circulating Tumor DNA Profiling Enables Superior and Universal Residual Disease Detection in Acute Myeloid Leukemia
Relapsed and/or refractory disease remains the leading cause of death in acute myeloid leukemia (AML), highlighting the need for broadly applicable, high-sensitivity approaches to measurable residual disease (MRD) detection. We developed...
06
DOI 10.1158/2643-3230.bcd-26-0046
Open DOI
Germline Noncoding Risk Variants Influence Clonal Hematopoiesis through Altered Hematopoietic Enhancer Activity
Clonal hematopoiesis of indeterminate potential (CHIP) is a precursor condition characterized by the expansion of mutant hematopoietic stem and progenitor cell (HSPC) clones that increase the risk of hematologic malignancies. Although ge...
07
DOI 10.1158/2643-3230.bcd-25-0501
Open DOI
Tumor CD19 Expression Determines Distinct Clinical Outcomes after CD19 CAR T-cell Therapy in Large B-cell Lymphoma
It remains uncertain whether lower CD19 expression is clinically relevant for outcomes of CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy for large B-cell lymphoma (LBCL). We conducted an integrative analysis of tumor CD19...
08
DOI 10.1158/2643-3230.bcd-26-0319
Open DOI
A (Post)translational Opportunity in RAS-Dependent Heme Malignancy
Summary: Zhang and colleagues uncover a mechanism of regulation of RAS stability that is active almost exclusively in hematologic (heme) malignancies. This provides new insights into the consequences of a RAS hotspot mutation found in le...
09
DOI 10.1158/2643-3230.bcd-25-0482
Open DOI
RHOA Deletion Downregulates CD19 and Promotes Dysfunctional Immune Microenvironments in CAR T–Resistant Large B-cell Lymphomas
CD19-directed chimeric antigen receptor (CAR-19) T cells are breakthrough therapies for large B-cell lymphomas (LBCL), but fewer than half of patients achieve durable responses. We previously showed that RHOA deletions are enriched in pr...
10
DOI 10.1158/2643-3230.bcd-26-0030
Open DOI
Therapy-Persistent Leukemia Is Selectively Vulnerable to SLC23A1 Restoration via Targeting KHSRP
Acute myeloid leukemia (AML) is prone to relapse driven by therapy-persistent residual cells. To discover specific vulnerabilities in this population, we performed genome-wide CRISPR interference screens in leukemia cells treated with mu...
Bibliographical & Catalog Notes
Online articles are published and made available via publisher's OnlineFirst as received before appearing in print.
Also issued in print.